Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Pancreatic Cancer Oncologists in the U.S.

Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 21, 2006
Fentora for pain
Analysis of: U.S. OKs New Cephalon Cancer Pain Drug (www.medscape.com)
Will Fentora have a major impact on the pain control market?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 20, 2006
Oral anticoagulation
Analysis of: Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications (www.pipelinereview.com)
The new Xa inhibitor will finally give us a coumadin alternative?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
October 24, 2006
Vectibix VS Erbitux
Analysis of: FDA Approves a New Drug for Colorectal Cancer, Vectibix (www.fda.gov)
Will Vectibix impact on Erbitux's market?  
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
October 24, 2006
Taxotere added to head and neck cancer therapy
Analysis of: Taxotere Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer (pharmalive.com)
The recent randomized study of Taxotere added to the age old 5FU + cisplatin will result in major adoption of the third agent
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
October 24, 2006
Rituxan is standard of NHL care
Analysis of: Rituximab Gains Two New Indications (www.ptcommunity.com)
What impact will the new indications, i.e., upfront low grade NHL treatment and diffuse large cell NHL treatment have on Rituxan.
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
October 24, 2006
Small cell lung cancer AND Alimta
Analysis of: Lilly Launches Phase III 'GALES' Trial of Alimta (Pemetrexed for Injection) in Small Cell Lung Cancer (pharmalive.com)
The Alimta chemo agent will somehow impact the standard treatment approach, i.e., etoposide + platinum in small cell lung cancer.

Previous Page : 1 2 3 4 5 6 7 8 9 1091 to 96 of 96

Analytics


Generated at 2009-01-07T19:00:58.307